Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5059166A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 11, 1989 |
| Grant date | Oct 22, 1991 |
| Priority date | — |
| Expiry date | Dec 11, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61F2210/0095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Intra-arterial stents are frequently used subsequent to balloon angioplasty to maintain arterial patency. The most frequent cause for failure to maintain patency is the rapid growth of the injured arterial tissue through the openings in the stent, which rapid growth is called "intimal hyperplasia." Since irradiation from a radioisotope source is capable of selectively inhibiting the growth of hyperproliferating cells as compared with normal cells, a radioisotope material which forms part of the stent can be used to decrease the rate of arterial reclosure. The radioisotope could be placed inside the stent, alloyed into the metal from which the stent is made, or preferably, it can be coated onto the stent's exterior surface. Beta emitting radioisotopes having a half-life between 1 and 100 days would be best suited as a stent coating because of their comparatively short range of action within human tissue, and because of their comparatively short half-life. An anti-thrombogenic coating placed on the outer surface of the radioisotope stent would further reduce arterial reclosure by decreasing stent thrombogenicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.